Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOX5 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the NADPH oxidase 5 (NOX5) gene. NOX5 is a calcium-dependent enzyme that generates reactive oxygen species (ROS), such as superoxide, which act as signaling molecules in various cellular processes, including proliferation and survival. In the context of oncology, particularly in melanoma and esophageal adenocarcinoma, NOX5 expression is often elevated. Silencing NOX5 via siRNA leads to a reduction in ROS production, which in turn modulates downstream signaling pathways like Akt and GSK-3β, ultimately increasing the levels of the cell cycle inhibitor p27Kip1 and inhibiting tumor cell growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NOX5 siRNA.